Last reviewed · How we verify
NCT07144046: TAPES
Tape Application Protocol for Enhanced Scars
NA trial testing Micropore covering of the medial half of the scar in Scar Improvement in 90 participants. Not yet recruiting.
1 September 2027
Quick facts
| Lead sponsor | Herlev Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 1 September 2025 |
| Primary completion | 1 September 2027 |
| Estimated completion | 1 September 2028 |
Drugs / interventions tested
- Micropore covering of the medial half of the scar
Conditions studied
- Scar Improvement — all drugs for Scar Improvement →
- Cosmetic Outcome — all drugs for Cosmetic Outcome →
Sponsor
Herlev Hospital
Who can join
Adults 18 to 80, female only, with Scar Improvement or Cosmetic Outcome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
What is the purpose of this study? The Investigators want to find out whether applying Micropore surgical tape to the medial half of the mastectomy scar for 3 months helps improve its appearance after 12 months, compared to no intervention. Why is this study important? Scars can cause discomfort and affect how people feel about their bodies. The tape is thought to reduce stress on healing skin and possibly lead to a better-looking scar. But The Investigators need strong evidence to know whether it really helps. How will the study be done? This is a randomized, observer-blinded trial. Women having mastectomy are randomly assigned to either receive the tape on half their scar or receive no tape. A plastic surgeon and a breast surgeon-who do not know which side had tape-will evaluate wounds using photos after 3 and 12 months. Patients will also rate their scars using a questionnaire (POSAS), giving their personal view on color, thickness, stiffness, and symptoms like itch or pain. What else are The Investigators looking at? The Investigators will examine whether the treated half of the scar looks better than the untreated half within the same woman-this helps control for individual skin differences. The Investigators will also compare treated versus untreated areas across different women to see if there is a consistent benefit. If the untaped half of scars looks different from control scars, this may suggest differences between the groups that affect results. What will this study reveal? It will show whether using the tape improves cosmetic outcomes after mastectomy, and whether patients and clinicians agree on how scars heal. The findings may guide better post-surgery care to reduce scars and improve confidence and quality of life.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07144046
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Herlev Hospital trials
Trials by the same sponsor.
- NCT07367412 — Zinc Supplementation and Infections in Older Medical Patients · NA · not yet recruiting
- NCT07171216 — The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bon · NA · recruiting
- NCT07272187 — Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions · recruiting
- NCT07117955 — Platelet-Rich Plasma for Peyronie's Disease · NA · recruiting
- NCT06974214 — Patient- and Family-centred Care in the Adult Intensive Care Unit: a Feasibility Study · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07144046 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Herlev Hospital
- Last refreshed: 27 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07144046.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing